EEF1A1P22: A Potential Drug Target and Biomarker (G645693)

Target Name: EEF1A1P22

NCBI ID: G645693

EEF1A1P22

Other Name(s): Eukaryotic translation elongation factor 1 alpha 1 pseudogene 22 | eukaryotic translation elongation factor 1 alpha 1 pseudogene 22

EEF1A1P22: A Potential Drug Target and Biomarker

Introduction

The protein EEF1A1P22, also known as Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 22, is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. It is a key regulator of the translation of Shang Xing proteins, which are involved in various cellular processes, including cell signaling, cell structure and function, and cell survival. EEF1A1P22 functions as a negative regulator of the translation machinery by binding to specific translation factors, preventing them from forming the complex required for protein translation.

Recent studies have identified EEF1A1P22 as a potential drug target in cancer therapy. Cancer is a leading cause of death worldwide, and its development and progression are closely associated with the regulation of gene expression. Therefore, targeting EEF1A1P22 and modulating its expression levels could provide new insights into cancer treatment and prevention.

Drugs that target EEF1A1P22 have the potential to inhibit its function as a negative regulator of protein translation, leading to increased protein translation and cell growth. This could result in the inhibition of the growth and spread of cancer cells, thereby having a positive impact on cancer treatment.

Expression of EEF1A1P22

EEF1A1P22 is a highly conserved protein that is expressed in various cell types, including human cancer cells. It is primarily expressed in the cytoplasm of eukaryotic cells and has been shown to play a role in the regulation of protein translation. EEF1A1P22 is composed of 214 amino acids acid residues and has a calculated molecular mass of 21.1 kDa.

It is well established that EEF1A1P22 functions as a negative regulator of protein translation by binding to specific translation factors. These factors are responsible for recognizing the start codon of the mRNA and initiating the translation machinery. By binding to these factors, EEF1A1P22 prevents them from forming the complex required for protein translation.

Expression of EEF1A1P22 has been shown to be regulated by various factors, including cellular signaling pathways, DNA methylation, and protein binding. For example, studies have shown that EOF1A1P22 can be regulated by the negative signaling pathway of the PI3K/AKT signaling pathway. This pathway is involved in the regulation of cell survival and growth, and is a potential target for anti-cancer drugs.

EEF1A1P22 has also been shown to be regulated by DNA methylation. Methylation of the promoter region of EEF1A1P22 has been shown to reduce its expression levels and enhance its stability. This suggests that methylation may play a role in the regulation of EEF1A1P22 expression and could be a potential target for cancer therapies.

Expression of EEF1A1P22 has also been influenced by various protein binding factors. For example, studies have shown that EEF1A1P22 can interact with the protein SSR1, which is involved in the regulation of protein translation. This interaction may influence the regulation of EEF1A1P22 expression and could be a potential target for cancer therapies.

In conclusion, EEF1A1P22 is a non-coding RNA molecule that plays a critical role in the regulation of protein translation in eukaryotic cells. Its expression and regulation by various factors, including DNA methylation and protein binding, make it a potential drug target in cancer therapy . Further research is needed to fully understand the role of EEF1A1P22 in cancer development and

Protein Name: Eukaryotic Translation Elongation Factor 1 Alpha 1 Pseudogene 22

The "EEF1A1P22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EEF1A1P22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets